Wound Healing Clinical Trial
Official title:
A 28-Day, Single-Center, Randomized, Comparator-Controlled, Proof-of-Principle Study to Assess Wound Healing Efficacies of Different Adhesive Bandages
Verified date | June 2023 |
Source | Johnson & Johnson Consumer and Personal Products Worldwide |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess the wound healing efficacy (time to complete healing) of different adhesive bandages.
Status | Completed |
Enrollment | 36 |
Est. completion date | October 30, 2019 |
Est. primary completion date | October 18, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 25 Years to 55 Years |
Eligibility | Inclusion Criteria: - Fitzpatrick Skin Type II or III - Uniform skin color on both volar forearms - Generally in good health based on medical history reported by the participant - -Individual has signed the Photographic Release and Informed Consent Documents along with (HIPAA) disclosure - Willing to have temporary (semi-permanent) dot-tattoos applied to the volar forearms Exclusion Criteria: - Has known allergies, hypersensitivity, or adverse reactions to anesthetics, adhesive bandages, latex, wound treatment products, or any component/ingredient present in the Investigational Products (IPs)/auxiliary/ancillary products - Has a known history of a blood-clotting disorder, keloid formation, or a cardiovascular, hepatic, or renal disease - Presents with a skin condition that would, in the opinion of the PI or Study Physician, confound study results, increase risk to participant, or interfere with study evaluations - Has excessive hair or tattoos on either volar forearm - Has a known history of severe systemic immune system disorders - Has self-reported Type 1 or Type 2 diabetes - Has self-reported uncontrolled chronic diseases - Is taking medication that would mask an adverse event, confound study results or alter/compromise the bleeding/healing process - Is self-reported to be pregnant or planning to become pregnant - Has a body mass index (BMI) above 35 - Is self-reported to be an alcohol or drug abuser - Has participated in another clinical trial within 10 days - Either is or lives with someone who is a current employee of any company that makes/markets adhesive bandages or first-aid products |
Country | Name | City | State |
---|---|---|---|
United States | Thomas J. Stephens | Richardson | Texas |
Lead Sponsor | Collaborator |
---|---|
Johnson & Johnson Consumer Inc. (J&JCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to Complete Wound Healing | Time to complete wound healing: time(in days) elapsed from time of wound creation to 12 PM of day (up to Day 16) on which composite healing score(CHS) first meets complete healing criterion of being at least a score of 8 (threshold for complete healing). CHS was calculated from clinical grading of wound healing parameters as general wound appearance (0 [Poor-New or fresh wound with epithelium layer missing, wound bed appears raw and possibly oozing] to 4 [Excellent-Fully healed, skin flush against surrounding skin, slight color mismatch may be present])+smoothness (0 [Rough, uneven wound]- 4 [complete smoothness, even wound])+epithelial confluence (0 [None]- 4 [91-100%full epithelial growth]) - erythema (0 [None]- 4 [Severe]) - edema (0 [None]- 4 [Severe]) - crusting/scabbing (0 [None]- 4 [90-100% crusting/scabbing]). CHS on 25-point scale (-12 [no healing] to +12 [towards healing]) is indicative of extent of wound healing and was calculated for each wound site at each evaluation day. | Up to Day 16 | |
Secondary | Change From Baseline in Trans-Epidermal Water Loss (TEWL) Measurements | Change from Baseline in TEWL was reported. TEWL is the passive transfer of water through stratum corneum and was measured for each wound site using Tewameter TM330T. TEWL is a non-invasive method to measure the integrity of stratum corneum barrier function. Tewameter probe measures the density gradient of the water evaporation from the skin indirectly by two pairs of sensors (temperature and relative humidity) inside a hollow cylinder. The probe was held in place on the skin for one measurement, for 40 sec, to ensure that a stable value has been established. The values of the last 10 sec are averaged as the actual measurement values. An increase in TEWL values shows damage to the skin barrier function. | Day 0 (immediate after wound creation), Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14 | |
Secondary | Change From Baseline in Clinical Grading of Wound Healing Parameter - Erythema | Change from baseline in Clinical grading of wound healing parameter (erythema) was evaluated on a scale of 0 (no erythema) to 4 (severe erythema). | Day 0 (immediate after wound creation), Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16 | |
Secondary | Change From Baseline in Clinical Grading of Wound Healing Parameter - Edema | Change from baseline in Clinical grading of wound healing parameter (edema) was evaluated on a scale of 0 (no edema) to 4 (severe edema). | Day 0 (immediate after wound creation), Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16 | |
Secondary | Change From Baseline in Composite Scar Score | Change from baseline in composite scar score was reported. It was calculated as the sum of the individual parameters on the Manchester Scar Scale (Color ranges 1 [perfect] to 4 [gross mismatch]), Finish ranges 1 [matte] to 2 [shiny], Contour ranges 1 [Flush with surrounding skin] to 4 [keloid], Distortion ranges 1 [none] to 4 [severe] and Texture ranges 1 [normal] to 4 [hard]). Composite Scar Scores range from 5 to 18, with 5 representing clinically best scars and 18 representing clinically worst scars. | Baseline and Day 28 | |
Secondary | Change From Baseline in Painful Score With Arm Resting by Side | Change from baseline in painful score based on participants self-assessment questionnaire score (question 1) was reported. Participants were asked to rate each wound for pain/soreness in resting position as score from 0 (no pain) to 10 (severe pain). | Baseline, Day 1, 2, 3 and 4 | |
Secondary | Change From Baseline in Painful Score With Arm in Normal Motion | Change from baseline in Painful Score based on participants self-assessment questionnaire score (question 3) was reported. Participants were asked to rate each wound for pain/soreness in normal position as score from 0 (no pain) to 10 (severe pain). | Baseline, Day 1, 2, 3 and 4 | |
Secondary | Change From Baseline in Itchy Score | Change from baseline in itchy score based on participants self-assessment questionnaire score (question 5) was reported. Participants were asked to rate each wound for itchiness as score from 0 (no itch) to 10 (severe itch). | Baseline, Day 1, 2, 3 and 4 | |
Secondary | Number of Participants With Pain Duration With Arm Resting by Side | Participants were asked to rate the pain as either brief, periodic, or constant in arm resting position with the Self-Assessment Questionnaire (question 2). Number of participants with pain duration (brief, periodic, or constant) with arm resting by side was reported. | Day 1, 2, 3 and 4 | |
Secondary | Number of Participants With Pain Duration With Arm in Normal Motion | Participants were asked to rate the pain as either brief, periodic, or constant in arm normal motion with the Self-Assessment Questionnaire (question 4). Number of participants with pain duration (brief, periodic, or constant) with arm in normal motion was reported. | Day 1, 2, 3 and 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05045183 -
A Study to Assess Wound Healing Efficacies of Different Clean, Treat, and Protect Wound Care Regimens Compared to Standard of Care and Untreated
|
N/A | |
Enrolling by invitation |
NCT04613336 -
Efficacy of Topical Heparin Spray on Donor Site Wound Healing Time Compared to Conventional Dressing Among Patients Undergoing Split Thickness Skin Grafting
|
||
Recruiting |
NCT02241811 -
Wound Treatment With 3% Sodium Pentaborate Pentahydrate
|
Phase 1 | |
Completed |
NCT02797899 -
Effect of PRF Palatal Bandage on Pain Scores and Wound Healing After Free Gingival Graft
|
N/A | |
Completed |
NCT01227759 -
Tyrosur® Gel-Investigation on Wound Healing Efficacy
|
Phase 2 | |
Completed |
NCT01061502 -
Efficacy Study of a Bioelectric Dressing to Treat Skin Graft Donor Site Wounds
|
Phase 1/Phase 2 | |
Completed |
NCT00736593 -
A Study Evaluating Nexagon™ in the Treatment of Skin Wounds.
|
Phase 1 | |
Completed |
NCT00977951 -
Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03872544 -
Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
|
||
Enrolling by invitation |
NCT03880188 -
Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
|
||
Recruiting |
NCT05191082 -
Manufacturing, Characterization and Evaluation of the Effect of Silk Fibroin Membranes, Loaded or Not With Neurotensins on Open Wounds in the Palate
|
N/A | |
Enrolling by invitation |
NCT05942235 -
The Use of Microlearning in Nursing Education
|
||
Completed |
NCT03433820 -
Wound Healing in Healthy Volunteers
|
N/A | |
Withdrawn |
NCT02383992 -
Postoperative Care of Sutured Wounds
|
N/A | |
Recruiting |
NCT02034539 -
VADOplex Critical Limb Ischemia Study
|
Phase 2/Phase 3 | |
Recruiting |
NCT01680042 -
Clinical Effect of Phenytoin Mucoadhesive Paste on Wound Healing After Oral Biopsy
|
Phase 1 | |
Completed |
NCT01734317 -
An Open Single-centre Investigation Evaluating Efficacy in Second Degree Partial Thickness Burns Using a Silicone Contact Layer Containing Silver.
|
N/A | |
Completed |
NCT01115218 -
The Influence of Anterior Chamber Fluid Mediators on the Success Rate of Trabeculectomy
|
||
Withdrawn |
NCT01008111 -
Wound Healing of Incisional Wounds for Bilateral Hernia Repair
|
Phase 1 | |
Completed |
NCT00984503 -
Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites
|
Phase 2 |